-2.61% for AstraZeneca stock as Cidel Asset Management Inc. cuts stake

Traders Union
All News
Financial News
AstraZeneca drops 2.61% to GBX14974.00

Highlights

AstraZeneca's Imfinzi achieved positive Phase III results in liver cancer, significantly delaying disease progression and strengthening its oncology pipeline outlook.
Institutional investors including Perpetual Ltd and Cidel Asset Management trimmed AstraZeneca holdings as the Parkinson’s therapy trial with Bydureon failed to meet efficacy targets.
AZN trades with a broadly bullish technical structure but faces potential short-term profit-taking; the price is expected to oscillate in a GBX 14,400–15,200 range, with a high probability of upward breakout if resistance is surpassed.

Positive liver cancer data contrasts with investor selling and weak Parkinson’s results

AstraZeneca reported positive Phase III results for its liver cancer therapy Imfinzi, which demonstrated significant slowing of disease progression. The company also participated in a recent Phase III trial of Bydureon (exenatide) for Parkinson's disease, but that study did not achieve the desired outcome in slowing motor symptom progression. Institutional investors such as Perpetual Ltd and Cidel Asset Management Inc. were noted to have reduced their holdings in AstraZeneca, though price action has remained under broader selling pressure.

Intraday profit taking emerges amid mixed overbought signals

Daily momentum signals are mixed for AZN: MACD and ADX on the daily chart are neutral, while RSI is near overbought at 66.48. Both CCI and Bull/Bear Power (BBP) indicate overbought conditions, with the Stoch RSI also confirming an overbought state and the Awesome Oscillator supporting the prevailing upside trend. AZN opened with a gap down from the previous close and is trading near today's low at GBX 14,944.00, reflecting a 2.61% decline and moderate intraday volatility. This ongoing downside movement is in partial divergence from more robust longer-term signals and may indicate short-term profit taking within an otherwise bullish trend.

High probability of sideways move as weekly momentum remains bullish

Over the next five trading days, AZN is expected to fluctuate within a typical volatility band between GBX 14,400 and GBX 15,200. The probability of further upside is very high (more than 80%), supported by bullish signals from all key weekly indicators (RSI, ADX, MACD, MA-50). The main scenario calls for continued sideways movement between GBX 14,400 and GBX 15,200. A decisive move above GBX 15,200 could trigger accelerated gains, while a sustained break below GBX 14,400 may lead to a deeper correction.

Viktoras Karapetjanc, expert at Traders Union, sees AstraZeneca’s robust trend structure as underpinned by strong fundamentals and positive sentiment despite some recent profit taking. He believes the company’s latest clinical results and active institutional activity keep the longer-term outlook constructive. Near-term volatility is expected, but technical and weekly signals remain clearly bullish. In his view, the current consolidation offers opportunity within the broader uptrend. "I expect AstraZeneca to continue outperforming, with a decisive move above GBX 15,200 likely to unlock further gains."

Earlier, analysts noted that AstraZeneca’s consistent bullish technical profile and positive clinical developments positioned the stock for continued strength. The current mixed short-term momentum amid overbought signals suggests traders should watch for a potential range breakout above GBX 15,200 as confirmation of renewed upward momentum.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.